. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 Nov;30(11):1728-36. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Gammagard®

News

  1. Chicago: More Phase 2 News—PBT2 and IVIg
  2. Research Brief: Octapharma IVIg Iffy in Phase 2 Trial